Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.41 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.41 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055985 | 0.89 | HTT (0.50) | KDM4ECYP3A4HSD17B10MKNK1ALDH1A1 | |
| Fumaric Acid SCHEMBL27601350 | 0.76 | KDM4E (0.56) | KDM4ECYP3A4HSD17B10ALDH1A1PMP22 | |
| Fumaric Acid SCHEMBL27619902 | 0.76 | KDM4E (0.60) | KDM4ECYP3A4HSD17B10ALDH1A1PMP22 | |
| Quipazine SCHEMBL29868311 | 0.74 | KDM4E (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1PMP22 | |
| Quipazine SCHEMBL10529419 | 0.74 | KDM4E (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1PMP22 | |
| Quipazine SCHEMBL124520 | 0.74 | KDM4E (1.00) | KDM4ECYP3A4HSD17B10ALDH1A1PMP22 | |
| Fumaric Acid SCHEMBL27601353 | 0.74 | BPTF (0.74) | KDM4ECYP3A4HSD17B10ALDH1A1PMP22 | |
| SCHEMBL31241183 | 0.74 | POLB (0.67) | MKNK1ALDH1A1MAPTRAB9AHTT | |
| SCHEMBL15552711 | 0.73 | HTT (0.49) | KDM4ECYP3A4HSD17B10ALDH1A1PMP22 | |
| Fumaric Acid SCHEMBL11602330 | 0.71 | KDM4E (0.60) | KDM4ECYP3A4HSD17B10ALDH1A1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100398103-C | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH AS (DK) | 2008-07-02 | — | — | CN | disclosed |
| CN-1635877-A | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH AS (DK) | 2005-07-06 | — | — | CN | disclosed |